ArticleBMC rheumatology2025
The risk factors of cerebral small vessel disease in patients with Systemic Lupus Erythematosus.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the treatment of eosinophilic granulomatosis with polyangiitis.Nature reviews. Rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCerebral small vessel disease (CSVD) imposes a significant burden on patients with systemic lupus erythematosus (SLE) and adversely impacts their health.
objectiveTo identify risk factors for CSVD in SLE patients and evaluate the clinical features of SLE patients with CSVD.
methodsData from SLE patients at Zhong Da Hospital affiliated with Southeast University (Nanjing, Jiangsu Province, China) were retrospectively collected from June 2013 to April 2022. Patients with CSVD were compared with those without brain parenchymal lesions as detected by Magnetic resonance imaging (MRI). Variables between the two groups were analyzed using the independent sample t-test, Mann-Whitney U test, chi-square test, or Fisher’s exact test. Logistic regression analysis was employed to identify risk factors for CSVD.
resultsA total of 100 SLE patients were included, of whom 60 had CSVD. Patients with CSVD were significantly older than those in the control group (48.5 vs. 39.5 years; P = 0.001), though gender distribution and disease duration were comparable between the groups. While clinical manifestations did not differ significantly between the groups, SLE patients with CSVD exhibited higher SLEDAI scores (8 vs. 6, P = 0.046). Hypertension was more common in the CSVD group (28.3% vs. 10.0%, P = 0.027). Additionally, the CSVD group demonstrated a higher prevalence of anti-β2GP1 antibody positivity (51.0% vs. 23.1%, P = 0.007), a greater proportion of patients with low C3 levels (78.4% vs. 54.1%, P = 0.015), and prolonged Activated Partial Thromboplastin Time (APTT) (32.7s vs. 31.4s, P = 0.028). Univariate and multivariate logistic regression analyses identified age (OR 1.062, 95% CI 1.010–1.116; P = 0.020), anti-β2GP1 positivity (OR 3.689, 95% CI 1.243–10.950; P = 0.019), and low C3 levels (OR 3.834, 95% CI 1.318–11.159; P = 0.014) as risk factors for CSVD in SLE patients.
conclusionsOur study revealed that SLE patients with CSVD tended to be older and more often presented with hypertension, positive anti-β2GP1 antibodies, lower C3 levels, higher SLEDAI scores, and prolonged APTT. Notably, advanced age, anti-β2GP1 positivity, and low C3 levels emerged as potential risk factors for CSVD development in SLE patients. These findings highlight the importance of these factors in the clinical management of SLE patients at risk of CSVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.